ACAD
37.79
+0.39
+1.04%
AEMD
0.21
+0.04
+24.70%
APRI
2.39
-0.18
-7.00%
ARNA
4.75
+0.04
+0.85%
ATEC
1.42
+0.07
+5.19%
CFN
60.22
0.00
0.00%
CNAT
6.46
+0.01
+0.16%
CRXM
0.21
+0.01
+5.85%
CYTX
1.18
+0.46
+63.67%
DXCM
61.88
-1.46
-2.31%
GNMK
12.95
+0.04
+0.31%
HALO
15.25
+0.08
+0.53%
ILMN
198.87
+2.65
+1.35%
INNV
0.17
-0.02
-9.29%
INO
7.04
+0.1
+1.44%
ISCO
0.06
+0.00
+4.90%
ISIS
67.31
-0.84
-1.23%
LGND
55.9
-0.8
-1.40%
LPTN
2.99
0.00
0.00%
MBVX
0.91
-0.05
-5.21%
MEIP
5.95
+0.3
+5.31%
MNOV
3.57
+0.04
+1.13%
MRTX
23.87
+0.55
+2.36%
MSTX
0.54
-0.01
-2.49%
NBIX
39.94
+0.35
+0.88%
NUVA
44.86
-0.64
-1.41%
ONCS
0.37
-0.01
-3.48%
ONVO
6.03
-0.15
-2.43%
OREX
5.87
+0.02
+0.34%
OTIC
35.17
+1.25
+3.69%
QDEL
26.04
+0.36
+1.40%
RCPT
126.04
+3.71
+3.03%
RGLS
19.18
+0.37
+1.97%
RMD
64.25
-1.02
-1.56%
SCIE
0.02
+0.00
+20.00%
SPHS
0.5
+0.03
+6.27%
SRNE
13.3
+0.12
+0.91%
TROV
5.54
+0.35
+6.74%
VICL
1.01
-0.03
-2.88%
VOLC
17.99
0.00
0.00%
ZGNX
1.65
+0.02
+1.23%
Home » Bio: Keith Murphy

Bio: Keith Murphy

Keith Murphy, chairman and chief executive officer, is a veteran of biotechnology startup Alkermes, Inc, where he played a central role on the development team for their first approved product, Nutropin (hGH) Depot. He moved to Amgen in 1997 and developed several other novel formulation and device products. He has more than 17 years of experience in biotechnology, including serving in product strategy and director of process development roles at Amgen. His 10 years at Amgen included four years as global operations leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. He holds a B.S. in chemical engineering from MIT and is an alumnus of the UCLA Anderson School of Management.